Proprietary AI analyst is now available
- Public Comps
- Editas Medicine
Editas Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Editas Medicine and similar public comparables like Emergent BioSolutions, Abclon, Sagimet Biosciences, Century Therapeutics and more.
Editas Medicine Overview
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Founded
2013
HQ

Employees
246
Website
Financials (LTM)
EV
$306M
Valuation Multiples
Start free trialEditas Medicine Financials
Editas Medicine reported last 12-month revenue of $28M and negative EBITDA of ($133M).
In the same LTM period, Editas Medicine generated $28M in gross profit, ($133M) in EBITDA losses, and had net loss of ($136M).
Revenue (LTM)
Editas Medicine P&L
In the most recent fiscal year, Editas Medicine reported revenue of $41M and EBITDA of ($149M).
Editas Medicine is unprofitable as of last fiscal year, with EBITDA margin of (367%) and net margin of (395%).
Financial data powered by Morningstar, Inc.
Editas Medicine Stock Performance
Editas Medicine has current market cap of $413M, and enterprise value of $306M.
Market Cap Evolution
Editas Medicine's stock price is $2.69.
Editas Medicine share price decreased by 21.8% in the last 30 days, and increased by 22.3% in the last year.
Editas Medicine has an EPS (earnings per share) of $-1.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $306M | $413M | 5.5% | -21.8% | 8.9% | 22.3% | $-1.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEditas Medicine Valuation Multiples
Editas Medicine trades at 10.8x EV/Revenue multiple, and (2.3x) EV/EBITDA.
EV / Revenue (LTM)
Editas Medicine Financial Valuation Multiples
As of June 19, 2026, Editas Medicine has market cap of $413M and EV of $306M.
Editas Medicine has a P/E ratio of (3.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Editas Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Editas Medicine Margins & Growth Rates
Editas Medicine decreased revenue by 65% and EBITDA by 28% in the last fiscal year.
In the most recent fiscal year, Editas Medicine reported EBITDA margin of (367%) and net margin of (395%).
Editas Medicine Margins
Editas Medicine Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Editas Medicine Operational KPIs
Editas Medicine's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.
Editas Medicine's Rule of 40 is (807%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Editas Medicine's Rule of X is (904%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Editas Medicine Competitors
Editas Medicine competitors include Emergent BioSolutions, Abclon, Sagimet Biosciences, Century Therapeutics, Benitec Biopharma, Ocugen, Formycon, Kamada, PureTech Health and Regenxbio.
Most Editas Medicine public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.1x | 1.1x | 3.5x | 4.3x | |||
| 126.3x | - | (36.4x) | - | |||
| - | - | (5.4x) | - | |||
| 3.0x | 5.6x | 125.0x | - | |||
| - | - | (5.6x) | - | |||
| 95.4x | 95.9x | (7.0x) | - | |||
| 6.5x | 5.4x | (330.1x) | (347.8x) | |||
| 2.0x | 1.9x | 8.6x | 7.7x | |||
This data is available for Pro users. Sign up to see all Editas Medicine competitors and their valuation data. Start Free Trial | ||||||
Editas Medicine VC Funding History
Before going public, Editas Medicine raised $210M in total equity funding, across 3 rounds.
Editas Medicine Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Editas Medicine
| When was Editas Medicine founded? | Editas Medicine was founded in 2013. |
| Where is Editas Medicine headquartered? | Editas Medicine is headquartered in United States. |
| How many employees does Editas Medicine have? | As of today, Editas Medicine has over 246 employees. |
| Who is the CEO of Editas Medicine? | Editas Medicine's CEO is Gilmore O’Neill. |
| Is Editas Medicine publicly listed? | Yes, Editas Medicine is a public company listed on Nasdaq. |
| What is the stock symbol of Editas Medicine? | Editas Medicine trades under EDIT ticker. |
| When did Editas Medicine go public? | Editas Medicine went public in 2016. |
| Who are competitors of Editas Medicine? | Editas Medicine main competitors include Emergent BioSolutions, Abclon, Sagimet Biosciences, Century Therapeutics, Benitec Biopharma, Ocugen, Formycon, Kamada, PureTech Health, Regenxbio. |
| What is the current market cap of Editas Medicine? | Editas Medicine's current market cap is $413M. |
| What is the current revenue of Editas Medicine? | Editas Medicine's last 12 months revenue is $28M. |
| What is the current revenue growth of Editas Medicine? | Editas Medicine revenue growth (NTM/LTM) is (49%). |
| What is the current EV/Revenue multiple of Editas Medicine? | Current revenue multiple of Editas Medicine is 10.8x. |
| Is Editas Medicine profitable? | No, Editas Medicine is not profitable. |
| What is the current EBITDA of Editas Medicine? | Editas Medicine has negative EBITDA and is not profitable. |
| What is Editas Medicine's EBITDA margin? | Editas Medicine's last 12 months EBITDA margin is (470%). |
| What is the current EV/EBITDA multiple of Editas Medicine? | Current EBITDA multiple of Editas Medicine is (2.3x). |
| What is the current FCF of Editas Medicine? | Editas Medicine's last 12 months FCF is ($145M). |
| What is Editas Medicine's FCF margin? | Editas Medicine's last 12 months FCF margin is (512%). |
| What is the current EV/FCF multiple of Editas Medicine? | Current FCF multiple of Editas Medicine is (2.1x). |
| How many companies Editas Medicine has acquired to date? | Editas Medicine hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Editas Medicine has invested to date? | Editas Medicine hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Editas Medicine
Lists including Editas Medicine
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.